We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
- Recent BSX Stock Price: $48.5
- Yearly Gain for BSX stock: 12.39%
- Market Cap for BSX stock: $68.09B
- P/E Ratio for BSX stock: 107.467
Will BSX's stock price go up? Is there an accurate BSX stock forecast available?
TipRanks.com reports that Boston Scientific currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $53.64. The target pricing ranges from a high BSX forecast of $56.00 down to a low forecast of $50.00. Boston Scientific (BSX)’s last closing stock price was $48.5 which would put the average price target at 10.60% upside.
In addition, TradingView issued a Strong Buy rating for BSX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BSX stock.
Other analysts covering BSX include:
- Robbie Marcus of J.P. Morgan issued a Buy rating with the price target of $ 55 on 1 day ago
- Travis Steed of Bank of America Securities issued a Buy rating with the price target of $ 55 on 1 day ago
- Anthony Petrone of Mizuho Securities issued a Hold rating with the price target of $ 52 on 1 day ago
- Matthew Taylor of Jefferies issued a Buy rating with the price target of $ 55 on 1 day ago
If you are wondering if BSX is a good stock to buy, here are 3rd party ratings for BSX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 41% (148 out of 250)
What is the sentiment on the street regarding Boston Scientific? (Current ratings compiled by TipRanks.com)
- News Sentiment for BSX stock: Neutral
- Blogger Consensus for BSX stock: Bullish
- Media Buzz for BSX stock: Low
- Insider Signal for BSX stock: Negative
- Investor Sentiment for BSX stock: Positive
- Hedge Fund signal for BSX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on BSX stock including scouring the social networks like BSX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BSX stock chart >>
Summary: Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
- Recent GILD Stock Price: $84.5
- Yearly Gain for GILD stock: 30.14%
- Market Cap for GILD stock: $105.36B
- P/E Ratio for GILD stock: 30.778
Will GILD's stock price go up? Is there an accurate GILD stock forecast available?
TipRanks.com reports that Gilead Sciences currently has 19 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $91.53. The target pricing ranges from a high GILD forecast of $112.00 down to a low forecast of $80.00. Gilead Sciences (GILD)’s last closing stock price was $84.5 which would put the average price target at 8.32% upside.
In addition, TradingView issued a Buy rating for GILD stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GILD stock.
Other analysts covering GILD include:
- Do Kim of Piper Sandler issued a Buy rating with the price target of $ 112 on 21 hours ago
- David Risinger of SVB Securities issued a Hold rating with the price target of $ 91 on 21 hours ago
If you are wondering if GILD is a good stock to buy, here are 3rd party ratings for GILD stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Gilead Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for GILD stock: Very Bullish
- Blogger Consensus for GILD stock: Bullish
- Media Buzz for GILD stock: Very High
- Insider Signal for GILD stock: Negative
- Investor Sentiment for GILD stock: Negative
- Hedge Fund signal for GILD stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on GILD stock including scouring the social networks like GILD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for GILD stock chart >>
Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
- Recent MCK Stock Price: $362.58
- Yearly Gain for MCK stock: 37.87%
- Market Cap for MCK stock: $52.60B
- P/E Ratio for MCK stock: 16.804
Will MCK's stock price go up? Is there an accurate MCK stock forecast available?
TipRanks.com reports that McKesson currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $428.91. The target pricing ranges from a high MCK forecast of $450.00 down to a low forecast of $376.00. McKesson (MCK)’s last closing stock price was $362.58 which would put the average price target at 18.29% upside.
In addition, TradingView issued a Sell rating for MCK stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MCK stock.
Other analysts covering MCK include:
- Erin Wright of Morgan Stanley issued a Buy rating with the price target of $ 426 on 1 day ago
- Lisa Gill of J.P. Morgan issued a Buy rating with the price target of $ 432 on 1 day ago
- Michael Cherny of Bank of America Securities issued a Buy rating with the price target of $ 450 on 1 day ago
- Steven Valiquette of Barclays issued a Buy rating with the price target of $ 415 on 1 day ago
If you are wondering if MCK is a good stock to buy, here are 3rd party ratings for MCK stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Buy, Top 33% (83 out of 250)
What is the sentiment on the street regarding McKesson? (Current ratings compiled by TipRanks.com)
- News Sentiment for MCK stock: Very Bullish
- Blogger Consensus for MCK stock: Bullish
- Media Buzz for MCK stock: Very High
- Insider Signal for MCK stock: Negative
- Investor Sentiment for MCK stock: Positive
- Hedge Fund signal for MCK stock: Positive
The stock market is extremely volatile, and you need to do your own research on MCK stock including scouring the social networks like MCK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MCK stock chart >>
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
- Recent LLY Stock Price: $339.08
- Yearly Gain for LLY stock: 36.93%
- Market Cap for LLY stock: $338.16B
- P/E Ratio for LLY stock: 47.911
Will LLY's stock price go up? Is there an accurate LLY stock forecast available?
TipRanks.com reports that Eli Lilly & Co currently has 16 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $400.20. The target pricing ranges from a high LLY forecast of $455.00 down to a low forecast of $313.00. Eli Lilly & Co (LLY)’s last closing stock price was $339.08 which would put the average price target at 18.03% upside.
In addition, TradingView issued a Sell rating for LLY stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on LLY stock.
Other analysts covering LLY include:
- Mohit Bansal of Wells Fargo issued a Hold rating with the price target of $ 360 on 21 hours ago
- Carter Gould of Barclays issued a Buy rating with the price target of $ 400 on 21 hours ago
- Geoff Meacham of Bank of America Securities issued a Buy rating with the price target of $ 390 on 1 day ago
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $ 410 on 1 day ago
If you are wondering if LLY is a good stock to buy, here are 3rd party ratings for LLY stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Sell, Bottom 31% (173 out of 250)
What is the sentiment on the street regarding Eli Lilly & Co? (Current ratings compiled by TipRanks.com)
- News Sentiment for LLY stock: Bullish
- Blogger Consensus for LLY stock: Bullish
- Media Buzz for LLY stock: High
- Insider Signal for LLY stock: Negative
- Investor Sentiment for LLY stock: Positive
- Hedge Fund signal for LLY stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on LLY stock including scouring the social networks like LLY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LLY stock chart >>
Summary: Humana Inc. is a health care plan provider in the United States. The company provides health insurance benefits under Health Maintenance Organization, Private Fee-For-Service and Preferred Provider Organization plans. The company also provides other benefits with specialty products including dental, vision, and other supplementary benefits. Humana's medical and specialty insurance products allow members to access health care services primarily through its networks of health care providers. The company manages its business through the following segments: The Retail segment consists of Medicare benefits, which are marketed on a retail basis to individuals. The Group and Specialty segment comprises employer group commercial fully-insured medical and specialty health insurance benefits. The Healthcare Services - The segment consists of services offered to the company's health plan members as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs.
- Recent HUM Stock Price: $476.57
- Yearly Gain for HUM stock: 15.68%
- Market Cap for HUM stock: $64.98B
- P/E Ratio for HUM stock: 22.226
Will HUM's stock price go up? Is there an accurate HUM stock forecast available?
TipRanks.com reports that Humana currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $619.86. The target pricing ranges from a high HUM forecast of $652.00 down to a low forecast of $560.00. Humana (HUM)’s last closing stock price was $476.57 which would put the average price target at 29.79% upside.
In addition, TradingView issued a Strong Sell rating for HUM stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on HUM stock.
Other analysts covering HUM include:
- David Windley of Jefferies issued a Buy rating with the price target of $ 602 on 1 day ago
- Kevin Caliendo of UBS issued a Buy rating with the price target of $ 620 on 1 day ago
- Kevin Fischbeck of Bank of America Securities issued a Buy rating with the price target of $ 640 on 1 day ago
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $ 615 on 2 days ago
If you are wondering if HUM is a good stock to buy, here are 3rd party ratings for HUM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 40% (100 out of 250)
What is the sentiment on the street regarding Humana? (Current ratings compiled by TipRanks.com)
- News Sentiment for HUM stock: Very Bullish
- Blogger Consensus for HUM stock: Bullish
- Media Buzz for HUM stock: Very High
- Insider Signal for HUM stock: Negative
- Investor Sentiment for HUM stock: Very Positive
- Hedge Fund signal for HUM stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on HUM stock including scouring the social networks like HUM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for HUM stock chart >>
Summary: Cardinal Health Inc. is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company has two reporting segments: Pharmaceutical and Medical. The Pharmaceutical segment is the second largest pharmaceutical distributor in the United States and the largest nuclear pharmacy. Its products and services include pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services. The Medical segment manufactures products such as single-use surgical drapes, gowns and apparel; exam and surgical gloves; and fluid suction and collection systems and offers sterile and non-sterile procedure kits. These products are sold directly or distributed via third-party sources in the U.S., Canada, Europe, South America and the Asia/Pacific.'
- Recent CAH Stock Price: $78.67
- Yearly Gain for CAH stock: 53.08%
- Market Cap for CAH stock: $19.85B
- P/E Ratio for CAH stock: -16.399
Will CAH's stock price go up? Is there an accurate CAH stock forecast available?
TipRanks.com reports that Cardinal Health currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $87.00. The target pricing ranges from a high CAH forecast of $94.00 down to a low forecast of $76.00. Cardinal Health (CAH)’s last closing stock price was $78.67 which would put the average price target at 10.59% upside.
In addition, TradingView issued a Strong Buy rating for CAH stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CAH stock.
Other analysts covering CAH include:
- Ann Hynes of Mizuho Securities issued a Hold rating with the price target of $ 76 on 21 hours ago
- Lisa Gill of J.P. Morgan issued a Hold rating with the price target of $ 89 on 21 hours ago
- Eric Coldwell of Robert W. Baird issued a Buy rating with the price target of $ 94 on 21 hours ago
- Jonathan Yong of Credit Suisse issued a Hold rating with the price target of $ 92 on 21 hours ago
If you are wondering if CAH is a good stock to buy, here are 3rd party ratings for CAH stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 33% (83 out of 250)
What is the sentiment on the street regarding Cardinal Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for CAH stock: Very Bullish
- Blogger Consensus for CAH stock: Bullish
- Media Buzz for CAH stock: Medium
- Insider Signal for CAH stock: Neutral
- Investor Sentiment for CAH stock: Neutral
- Hedge Fund signal for CAH stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on CAH stock including scouring the social networks like CAH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CAH stock chart >>
Summary: N/A
- Recent SEMHF Stock Price: $52.996
- Yearly Gain for SEMHF stock: -10.83%
- Market Cap for SEMHF stock: $60.20B
- P/E Ratio for SEMHF stock: 31.134
Will SEMHF's stock price go up? Is there an accurate SEMHF stock forecast available?
TipRanks.com reports that Siemens Healthineers AG currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $64.59. The target pricing ranges from a high SEMHF forecast of $73.21 down to a low forecast of $54.47. Siemens Healthineers AG (SEMHF)’s last closing stock price was $52.996 which would put the average price target at 21.69% upside.
In addition, TradingView issued a Strong Buy rating for SEMHF stock over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SEMHF stock.
Other analysts covering SEMHF include:
- Thando Skosana of UBS issued a Buy rating with the price target of $ 65.36 on 21 hours ago
- Falko Friedrichs of Deutsche Bank issued a Buy rating with the price target of $ 69.72 on 21 hours ago
- Sezgi Oezener of HSBC issued a Buy rating with the price target of $ 64.27 on 21 hours ago
- James Vane of Jefferies issued a Hold rating with the price target of $ 54.47 on 1 day ago
If you are wondering if SEMHF is a good stock to buy, here are 3rd party ratings for SEMHF stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: n/a
What is the sentiment on the street regarding Siemens Healthineers AG? (Current ratings compiled by TipRanks.com)
- News Sentiment for SEMHF stock: Neutral
- Blogger Consensus for SEMHF stock: n/a
- Media Buzz for SEMHF stock: Very Low
- Insider Signal for SEMHF stock: Negative
- Investor Sentiment for SEMHF stock: n/a
- Hedge Fund signal for SEMHF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on SEMHF stock including scouring the social networks like SEMHF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SEMHF stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================